Amphastar Corp (AMPH) - Long-Term Debt to Capital Coefficient

Serving as the primary valuation tool, this Amphastar Pharmaceuticals (AMPH) price chart on the GURU.Markets platform demonstrates the asset's dynamics, whose returns are based on the sale of original and generic injectable drugs, as well as hospital supplies, reaching 0.81. Amphastar Pharmaceuticals (AMPH) delegates the initial testing phases to external contractors while maintaining internal quality control and its own production capacities. Stable management is effectively implementing a long-term development plan, ensuring a high level of shareholder confidence.

The assessment of the issuer's long-term reliability is based on the ratio of debt with a maturity of more than one year to equity, which allows for the measurement of financial leverage and the stress resilience of the balance sheet structure. An analysis of long-term debt to equity confirms the stability of Amphastar Pharmaceuticals (AMPH), whose localization of facilities in the US minimizes geopolitical risks and ensures the sustainability of payments on obligations.